IL17A and sarcomatoid mesothelioma: Elevated levels of interleukin 17 (IL17A), but no other cytokines, have been associated with immune-related neuroendocrine toxicity, characterized by insulin-dependent diabetes, hypophysitis and a myasthenic-like syndrome in a patient with sarcomatoid mesothelioma treated with dual immune checkpoint blockade (anti-PD-1 and anti-TIM3 Abs) (52).